Klaesson S, Ringdén O, Markling L, Remberger M, Lundkvist I
Department of Clinical Immunology, Karolinska Institute, Huddinge Hospital, Stockholm, Sweden.
Scand J Immunol. 1993 Nov;38(5):477-84. doi: 10.1111/j.1365-3083.1993.tb02591.x.
Intravenous Immunoglobulin (IVIG) at a concentration of 5 mg/ml, significantly inhibited mitogenic responses to phytohaemagglutinin (PHA), concanavalin A (conA) and pokeweed mitogen (PWM) by peripheral blood cells from healthy donors. No difference in inhibition by IVIG was seen when stimulating different T-lymphocyte cell subsets. Inhibition by IVIG was dose-dependent. An increased response was observed when IVIG was added more than 12 h after PHA compared to adding 1 h before [P = 0.05]. Intravenous immunoglobulin added to mixed lymphocyte cultures (MLC), reduced the median response by more than 60% (range 14-89%; P = 0.03) and almost completely abrogated the lymphocyte response to Staphylococcus aureus protein A (SPA), whose median inhibition was 94% (range 90-99%; P = 0.02). When comparing 12 different commercial IVIG preparations at a concentration of 2.5 mg/ml, the median inhibition of the PHA stimulation ranged from 4% to 35% and the MLC response from 0% to 66%. In the presence of IVIG the lymphocyte response to different herpes virus antigens was reduced by > 50%. No difference in inhibitory effect was seen when comparing IVIG and cytomegalovirus (CMV) hyper Ig, but CMV negative Ig resulted in lower inhibition [P = 0.05]. Three out of five IgG preparations (2.5 mg/ml) made from single donors inhibited PHA stimulation significantly more than commercial IVIG [P < 0.05]. Mean inhibition was 61% compared to 35%. Inhibition by pooled IgG from five donors was 56%. F(ab')2 fragments of IVIG inhibited the MLC response by more than 50% (range 34-75%), SPA stimulation by 97% (83-104%) and PHA stimulation by more than 30% (26-37%). One of two Fc preparations tested had an inhibitory effect, but the inhibition was less than that obtained with the F(ab')2 fragments [P = 0.04]. These results further strengthen the notion that IVIG exerts its immune modulatory effect by binding to leukocyte surface receptors. A clear inhibition was obtained with concentrations corresponding to the serum levels obtained when IVIG is given 250-500 mg/kg bodyweight. F(ab')2 fragments have the same inhibitory effect as intact IgG molecules but the role of Fc fragments still remains unclear. Differences in the immunosuppressive effect of various IVIG preparations may be associated with the method of preparation.
浓度为5毫克/毫升的静脉注射免疫球蛋白(IVIG)显著抑制了健康供体外周血细胞对植物血凝素(PHA)、刀豆球蛋白A(conA)和商陆有丝分裂原(PWM)的促有丝分裂反应。刺激不同的T淋巴细胞亚群时,IVIG的抑制作用无差异。IVIG的抑制作用呈剂量依赖性。与在PHA刺激前1小时添加IVIG相比,在PHA刺激后12小时以上添加IVIG时观察到反应增强[P = 0.05]。添加到混合淋巴细胞培养物(MLC)中的静脉注射免疫球蛋白使中位反应降低了60%以上(范围为14 - 89%;P = 0.03),并几乎完全消除了淋巴细胞对金黄色葡萄球菌蛋白A(SPA)的反应,其抑制中位值为94%(范围为90 - 99%;P = 0.02)。比较浓度为2.5毫克/毫升的12种不同商业IVIG制剂时,PHA刺激的抑制中位值为4%至35%,MLC反应的抑制中位值为0%至66%。在IVIG存在的情况下,淋巴细胞对不同疱疹病毒抗原的反应降低了> 50%。比较IVIG和巨细胞病毒(CMV)高免疫球蛋白时,未观察到抑制作用的差异,但CMV阴性免疫球蛋白导致的抑制作用较低[P = 0.05]。由单个供体制备的五种IgG制剂(2.5毫克/毫升)中有三种对PHA刺激的抑制作用明显大于商业IVIG [P < 0.05]。平均抑制率为61%,而商业IVIG为35%。来自五个供体的混合IgG的抑制率为56%。IVIG的F(ab')2片段抑制MLC反应超过50%(范围为34 - 75%),抑制SPA刺激97%(83 - 104%),抑制PHA刺激超过30%(26 - 37%)。测试的两种Fc制剂之一有抑制作用,但抑制作用小于F(ab')2片段[P = 0.04]。这些结果进一步强化了IVIG通过与白细胞表面受体结合发挥免疫调节作用的观点。当给予250 - 500毫克/千克体重的IVIG时,与所获得的血清水平相对应的浓度可产生明显的抑制作用。F(ab')2片段与完整的IgG分子具有相同的抑制作用,但Fc片段的作用仍不清楚。各种IVIG制剂免疫抑制作用的差异可能与制备方法有关。